- Home
- NUVL vs MKTX Comparison
NUVL vs MKTX Comparison
Compare NUVL & MKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NUVL | MKTX |
|---|---|---|
| Founded | 2017 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Bankers/Brokers/Service |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.1B | 6.0B |
| IPO Year | 2021 | 2004 |
Fundamental Metrics
Financial Performance| Metric | NUVL | MKTX |
|---|---|---|
| Price | $101.45 | $181.28 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 15 | 10 |
| Target Price | $135.00 | ★ $211.30 |
| AVG Volume (30 Days) | 485.1K | ★ 718.3K |
| Earning Date | 10-30-2025 | 02-05-2026 |
| Dividend Yield | N/A | ★ 1.67% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 5.87 |
| Revenue | N/A | ★ $839,263,000.00 |
| Revenue This Year | N/A | $6.33 |
| Revenue Next Year | N/A | $8.10 |
| P/E Ratio | ★ N/A | $31.08 |
| Revenue Growth | N/A | ★ 3.37 |
| 52 Week Low | $55.54 | $156.17 |
| 52 Week High | $112.88 | $232.84 |
Technical Indicators
Market Signals| Indicator | NUVL | MKTX |
|---|---|---|
| Relative Strength Index (RSI) | 45.84 | 60.95 |
| Support Level | $99.38 | $181.22 |
| Resistance Level | $106.65 | $184.39 |
| Average True Range (ATR) | 2.78 | 2.62 |
| MACD | -0.75 | 0.25 |
| Stochastic Oscillator | 24.04 | 68.52 |
Price Performance
Historical ComparisonAbout NUVL Nuvalent Inc.
Nuvalent Inc is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of the Company's operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically validated kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.
About MKTX MarketAxess Holdings Inc.
Founded in 2000, MarketAxess is a leading electronic fixed-income trading platform that connects broker/dealers and institutional investors. The company is primarily focused on credit based fixed income securities with its main trading products being US investment-grade and high-yield bonds, Eurobonds, and Emerging Market corporate debt. Recently the company has expanded more aggressively into Treasuries and municipal bonds with the acquisitions of LiquidityEdge and MuniBrokers in 2019 and 2021, respectively. The company also provides pre- and post-trade services with its acquisition of Regulatory Reporting Hub from Deutsche Börse Group in 2020 adding to its product offerings.